Jerini starts HAE Phase III

Jerini (Berlin, Germany) began the double-blind, placebo-controlled Phase III FAST 1 trial of its subcutaneous Icatibant in more than 50 patients in the U.S. and Canada with hereditary angioedema (HAE...